首页> 外文OA文献 >Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

【2h】

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

机译：长春瑞滨联合培妥珠单抗和曲妥珠单抗联合治疗HER2阳性局部晚期或转移性乳腺癌患者的一线治疗的安全性和有效性：VELVET研究组1的最终结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Edith A. Perez; José Manuel López-Vega; Thierry Petit; Claudio Zamagni; Valerie Easton; Julia Kamber; Eleonora Restuccia; Michael Andersson;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results [J] . Edith A. Perez, José Manuel López-Vega, Thierry Petit, Breast Cancer Research . 2016,第1期

机译：Vinorelbine与Pertuzumab和Trastuzumab组合的安全性和疗效与患有Her2阳性局部晚期或转移性乳腺癌患者的一线治疗：天鹅绒队队列1最终结果
2. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [J] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Trials . 2020,第1期

机译：Trastuzumab，Pertuzumab和Eribulin甲磺酸丁酯与曲妥珠单抗，Pertuzumab和紫罗兰作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势，III期的研究方案日本试验（JBCRG-M06 / Emerald）
3. Taxane versus vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with metastatic HER2-positive breast cancer - A retrospective two-center study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：紫杉烷与血管联系相结合，与Pertuzumab和Trastuzumab进行了转移患者的一线治疗患者的转移性Her2阳性乳腺癌 - 一个回顾性的双中心研究
4. 6.3 MeV Fast Neutrons in the Treatment of Patients with Locally Advanced and Locally Recurrent Breast Cancer [C] . V. V. Velikaya, L. I. Musabaeva, V. A. Lisin, International Conference on Physics of Cancer . 2016

机译：6.3 MeV快速中子治疗局部晚期和局部复发性乳腺癌的患者
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results [O] . Edith A. Perez, José Manuel López-Vega, Thierry Petit, 2016

机译：长春瑞滨联合培妥珠单抗和曲妥珠单抗联合用于HER2阳性局部晚期或转移性乳腺癌患者的一线治疗的安全性和有效性：VELVET研究组1的最终结果
7. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

著录项

引文网络

相似文献

相关主题

期刊订阅